SHR-4506 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-4506-101: A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors (clinicaltrials.gov) - P1 | N=102 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors (clinicaltrials.gov) - P1 | N=102 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1 trial • Solid Tumor

Hengrui Medicine (600276.SH): SHR-4506 Injection Receives Drug Clinical Trial Approval Notice (Sina Corp) - "Hengrui Medicine...announced that its subsidiary Suzhou Shengdia Biotechnology Co., Ltd. received the 'Drug Clinical Trial Approval Notice' for SHR-4506 Injection approved by the National Medical Products Administration and will conduct clinical trials in the near future."

New trial • Oncology